In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barré syndrome after individuals were vaccinated against COVID-19.
Both reports describe an unusual variant of Guillain-Barré syndrome characterized by prominent facial weakness. Seven cases were reported from a regional medical center in Kerala, India, where approximately 1.2 million people were vaccinated with the AstraZeneca COVID-19 vaccine. Four cases were reported from Nottingham, England, in an area in which approximately 700,000 people received the same vaccine. All eleven cases were among people who had received that vaccine between 10 and 22 days earlier.
The frequency of Guillain-Barré syndrome in these areas was estimated to be up to 10 times greater than expected.
“If the link is causal it could be due to a cross-reactive immune response to the SARS-CoV-2 spike protein and components of the peripheral immune system,” wrote the authors of the report from England.
The authors of both articles stress that clinicians should be vigilant in looking for this rare neurological syndrome following administration of COVID-19 vaccines.
No proof COVID vaccines can trigger Guillain-Barré syndrome
Boby Varkey Maramattom et al, Guillain ‐ Barré syndrome following ChAdOx1 ‐ S / nCoV ‐19 vaccine, Annals of Neurology (2021). DOI: 10.1002 / ana.26143
Christopher Martin Allen et al, Guillain ‐ Barré syndrome variant occurring after SARS ‐ CoV ‐2 vaccination, Annals of Neurology (2021). DOI: 10.1002 / ana.26144
Rare neurological disorder documented following COVID-19 vaccination (2021, June 21)
retrieved 21 June 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.